Sandra Hoffmann
Rheumatology · Saint Louis, MONPI 1477565893
Payments from drug & device makers
Across 1,167 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Pfizer$3K
- Mallinckrodt Hospital Products Inc.$3K
- Amgen$2K
- Novartis$2K
- Johnson & Johnson$1K
- plus $7K from 29 others
What the payments were for
- Food & beverage$22,61299%
- Education$580%
- Gifts$630%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 231 | $13,553 |
| Pfizer | 208 | $3,062 |
| Mallinckrodt Hospital Products Inc. | 88 | $2,917 |
| Amgen(2 entities) | 103 | $2,438 |
| Novartis | 97 | $1,660 |
| Johnson & Johnson | 88 | $1,473 |
| GSK | 57 | $1,051 |
| UCB, Inc. | 52 | $903 |
| E.r. Squibb & Sons, L.L.C. | 38 | $667 |
| Lilly USA, LLC | 40 | $663 |
| Mallinckrodt Enterprises LLC | 26 | $617 |
| AstraZeneca(2 entities) | 26 | $509 |
| Bristol Myers Squibb | 26 | $387 |
| ANI Pharmaceuticals, Inc. | 17 | $321 |
| Boehringer Ingelheim | 9 | $232 |
| Sanofi | 11 | $197 |
| Eisai Inc. | 9 | $194 |
| Radius Health, Inc. | 7 | $193 |
| Genentech USA, Inc. | 8 | $125 |
| Otsuka America Pharmaceutical, Inc. | 3 | $112 |
| Aurinia Pharma U.S., Inc. | 4 | $88 |
| Intrafusion GP, LLC | 1 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Organon | 2 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Ultragenyx Pharmaceutical Inc. | 2 | $30 |
| Novo Nordisk | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,733 in reported general payments places this provider in the 80th percentile of 134 rheumatology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 27 | $3,072,320 |
| Humira(Cf) PenAdalimumab | 121 | $1,445,801 |
| RinvoqUpadacitinib | 61 | $402,413 |
| Skyrizi PenRisankizumab-Rzaa | 18 | $390,183 |
| Humira PenAdalimumab | 18 | $273,714 |
| SkyriziRisankizumab-Rzaa | 11 | $249,732 |
| Cosentyx Sensoready PenSecukinumab | 24 | $188,489 |
| TremfyaGuselkumab | 13 | $188,233 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $159,972 |
| Enbrel SureclickEtanercept | 11 | $135,997 |
| Orencia ClickjectAbatacept | 15 | $87,750 |
| OtezlaApremilast | 11 | $51,165 |
| MounjaroTirzepatide | 21 | $23,928 |
| Hydroxychloroquine Sulfate | 688 | $17,154 |
| Mycophenolate Mofetil | 92 | $10,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $2,917 | $3,072,32027 claims |
| AbbVieRinvoq, Skyrizi | $13,553 | $652,14572 claims |
| Johnson & JohnsonTremfya | $1,473 | $188,23313 claims |
| AmgenOtezla | $2,438 | $51,16511 claims |
| Lilly USA, LLCMounjaro | $663 | $23,92821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in Saint Louis
- Alfred KimSaint Louis$1.2M
- Sona KamatSaint Louis$931K
- Akgun InceSaint Louis$849K
- Adam KilianSaint Louis$593K
- John BuddSaint Louis$404K
- Chad RonholmSaint Louis$327K
- Reema SyedSaint Louis$313K
- Richard BrasingtonSaint Louis$110K
- Barbara CacioloSaint Louis$98K
- Deborah ParksSaint Louis$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.